The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell …
The number of HLA-haploidentical hematopoietic cell transplants continues to increase
worldwide due to recent improvements in outcomes, allowing more patients with …
worldwide due to recent improvements in outcomes, allowing more patients with …
[HTML][HTML] Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding
NS Nunes, CG Kanakry - Frontiers in immunology, 2019 - frontiersin.org
Post-transplantation cyclophosphamide (PTCy) has been highly successful at preventing
severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic …
severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic …
[HTML][HTML] Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular …
AS Kanate, NS Majhail, BN Savani, C Bredeson… - Biology of Blood and …, 2020 - Elsevier
Abstract The American Society for Transplantation and Cellular Therapy (ASTCT) published
its first white paper on indications for autologous and allogeneic hematopoietic cell …
its first white paper on indications for autologous and allogeneic hematopoietic cell …
[HTML][HTML] Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
LP Wachsmuth, MT Patterson… - The Journal of …, 2019 - Am Soc Clin Investig
Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
BM Haverkos, D Abbott, M Hamadani… - Blood, The Journal …, 2017 - ashpublications.org
Given the limited treatment options for relapsed lymphoma post–allogeneic hematopoietic
cell transplantation (post–allo-HCT) and the success of programmed death 1 (PD-1) …
cell transplantation (post–allo-HCT) and the success of programmed death 1 (PD-1) …
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
RW Merryman, HT Kim, PL Zinzani… - Blood, The Journal …, 2017 - ashpublications.org
Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
tested in patients with advanced lymphoma. Following treatment, many of those patients are …
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
N Schmitz, L Truemper, K Bouabdallah… - Blood, The Journal …, 2021 - ashpublications.org
First-line therapy for younger patients with peripheral T-cell non-Hodgkin lymphoma (T-NHL)
consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone …
consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone …
Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin …
C Martínez, J Gayoso, C Canals, H Finel… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-
transplantation cyclophosphamide–based haploidentical (HAPLO) allogeneic hematopoietic …
transplantation cyclophosphamide–based haploidentical (HAPLO) allogeneic hematopoietic …
Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first …
S Yu, F Huang, Y Wang, Y Xu, T Yang, Z Fan, R Lin… - Leukemia, 2020 - nature.com
This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID)
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
A Rashidi, M Hamadani, MJ Zhang, HL Wang… - Blood …, 2019 - ashpublications.org
HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using
posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a …
posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a …